Effect of Low-Dose Aspirin on Candidate Biomarkers in the Urine Proteome

Youhe Gao

DOI: https://doi.org/10.15406/mojpb.2016.03.00087

2016-01-01

Abstract:A biomarker is a measurable change associated with a physiological or pathophysiological process.Unlike blood, which is homeostatic, urine is more likely to reflect changes in the body; urine is also a promising source of biomarker discovery because changes in physiology are accumulated in this fluid.However, urinary biomarker discovery remains a major challenge because the urinary proteome is influenced by various factors.Low-dose aspirin is widely used for preventing myocardial infarction, ischemic stroke and vascular death among patients at both high and low risk for these events as well as some cancers.Because animal models allow for controlling genetic and environmental factors, in this study, the effects of aspirin on the urinary proteome were analysed in rats.Urinary samples were collected before and at 7days after administration of low-dose aspirin (50mg/kg.d).A total of 191 proteins were identified by Nano LC-MS/MS and then quantified using Scaffold software.Twelve of these proteins were significantly altered, suggesting that aspirin affects the urinary proteome.Nine of the 12 proteins have been previously reported as candidate disease biomarkers, suggesting that these effects must be considered in future urinary biomarker research.Additionally, the changes in protein induced by low-dose aspirin were distinct from those caused by heparin and argatroban treatments; this indicates that the urinary proteome can distinguish blood coagulation status induced by different coagulation mechanisms, which may help in the design of more specific treatment plans for patients.Two significantly up-regulated proteins, pro-EGF and CD10, were selected for further validation by western blotting, and the results were consistent with those of mass spectrometry.Therefore, we propose that these two proteins may be used for monitoring platelet aggregation.